Business Wire

Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis

Share

Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker™. The new functionality complements Parse’s existing portfolio of Evercode immune products to enable a full end-to-end workflow for researchers.

Immunologists have lacked an integrated, purpose-built platform capable of connecting immune repertoire data with whole transcriptome single cell insights. As a result, interpreting clonal behavior, understanding functional cell states, and drawing meaningful biological conclusions has often required stitching together fragmented tools, custom code, or inconsistent visualization approaches. The new Trailmaker functionality directly addresses these challenges by providing an accessible, end-to-end immune profiling solution that brings repertoire and transcriptional information together in a cohesive environment.

The new functionality combines immune repertoire and whole transcriptome data to give researchers a complete view of clonal structure, diversity, and antigen-driven signatures. Users can visualize clonotypes and cell types on an integrated UMAP, quickly identify dominant clones with frequency and honeycomb plots, and use unique motif analysis to detect conserved patterns. By linking repertoire data with full transcriptome expression, Trailmaker makes it easy to connect clonotypes to their transcriptional states, reveal clonotype-specific gene programs, and run targeted differential expression, delivering deeper, more contextualized biological insights.

“Our goal has always been to remove barriers for researchers,“ says Charlie Roco, PhD, Co-founder and Chief Technology Officer at Parse. “By making immune profiling intuitive and more fully integrated, we’re empowering immunologists to spend less time wrangling the data and more time assigning biological significance.”

To learn more, attend the company’s upcoming educational webinar on January 29 at 8:00 AM Pacific Time: https://parse.bio/45bmrJT.

About Parse Biosciences

Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260122181379/en/

Contacts

Kaitie Kramer
kkramer@parsebiosciences.com | 858.504.0455

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting Strengthens Digital Transformation Offering with Silver Creek22.1.2026 15:30:00 CET | Press Release

Andersen Consulting announces a Collaboration Agreement with Silver Creek, a leader in data strategy, analytics, application development, and AI-powered automation services. Silver Creek Software is a premier technology services firm based in Alberta, Canada with expertise in transforming organizations through data and business solutions. Established in 1998, the firm offers full-service consulting, specializing in data and analytics, application development, machine learning, and AI. With a team of highly experienced and certified professionals, the firm delivers tailored solutions across multiple industries including public sector, financial services, natural resources, and transportation. At its core, Silver Creek’s focus is on getting value out of the client’s data through digitization, integration, and automation. “We’ve built our reputation on helping organizations turn complex data ecosystems into strategic assets,” said Ben Steem, CEO of Silver Creek. “By collaborating with And

Rimini Street Delivers First 20 Rimini Agentic UX™ Solutions That Solve a Variety of ERP Process Challenges Faster, Better and Cheaper with Agentic AI ERP22.1.2026 15:00:00 CET | Press Release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of its first 20 innovative Rimini Agentic UX™ Solutions, Powered by ServiceNow®. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122013155/en/ Rimini Street Delivers First 20 Rimini Agentic UX™ Solutions That Solve a Variety of ERP Process Challenges Faster, Better and Cheaper with Agentic AI ERP Solving Real Business Challenges Now with Agentic AI ERP Rimini Agentic UX Solutions are already in production and helping organizations achieve better business outcomes with savings, speed and agility – redefining how organizations support, optimize and innovate ERP Processes. Each Rimini Agentic UX Solution is purpose-built by ERP Process experts to solve a specific business challenge and deliver a time-to-value measured

LoungePair Brings on Former LoungeBuddy CEO, Enters Agreements with Vietnam Airlines, Auckland Airport22.1.2026 15:00:00 CET | Press Release

Travel-tech company LoungePair has brought on LoungeBuddy founder and former American Express executive Tyler Dikman as a key advisor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122515067/en/ Tyler Dikman, joins LoungePair as Key Advisor The company has also signed a key partnership with Vietnam Airlines to power its new Lotusmiles Lounges platform and has added Auckland Airport's Strata Lounge to its network. LoungePair provides on-demand and walk-up airport lounge access without the need for additional memberships, reward programmes, or loyalty status. Travel Tech Expert Tyler Dikman Joins as Advisor Tyler Dikman is the co-founder and former CEO of LoungeBuddy, the airport lounge booking platform acquired by American Express in 2019. Following the acquisition, he served as Vice President of Global Premium Products and Benefits at American Express, leading the integration of LoungeBuddy and helping shape travel exper

Lone Star Acquires Alliance Ground International22.1.2026 14:55:00 CET | Press Release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire Alliance Ground International (“AGI”), a leading North American airport services provider, from Greenbriar Equity Group and Audax Private Equity. Financial terms of the transaction were not disclosed. Founded in 1987 and headquartered in Miami, AGI operates in over 60 airports in North America with a workforce of more than 12,000 professionals. The company provides mission-critical, outsourced services that enable the efficient movement of cargo and passenger aircraft through major airport hubs. AGI’s core business is air cargo handling, supported by passenger terminal, ground handling and other related services. Its integrated service offering, strategic on-airport footprint and long-standing customer relationships position AGI as a trusted partner to cargo carriers and passenger airlines, supporting airport operations and global trade flows. L

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer22.1.2026 14:00:00 CET | Press Release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival (OS) primary endpoint. In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 35 percent reduction in the risk of death compared to patients treated with nab-paclitaxel alone (hazard ratio: 0.65; p-value: 0.0004). The median OS for patients receiving relacorilant was 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone, a difference of 4.1 months. Relacorilant in combination with nab-paclitaxel was well-tolerated, consistent with its known safety profile. Importantly, the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye